FDA keeps a firm grip on partial hold for troubled Repros Therapeutics, with big trial demand
The news isn’t getting any better at Repros Therapeutics $RPRX. Early Monday the Woodlands, TX-based biotech put out the word that the partial hold placed on the Proellex program will remain in place after regulators made clear that the biotech will need to assemble a “large” safety database on the drug ahead of any approval. And that report sent its already tattered shares into a fresh tailspin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.